Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

Graeme J Hankey, Manesh R Patel, Susanna R Stevens, Richard C Becker, Günter Breithardt, Antonio Carolei, Hans-Christoph Diener, Geoffrey A Donnan, Jonathan L Halperin, Kenneth W Mahaffey, Jean-Louis Mas, Ayrton Massaro, Bo Norrving, Christopher C Nessel, John F Paolini, Risto O Roine, Daniel E Singer, Lawrence Wong, Robert M Califf, Keith A A FoxWerner Hacke, ROCKET AF Steering Committee Investigators

    325 Citationer (Scopus)

    Abstract

    In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA).
    OriginalsprogEngelsk
    TidsskriftLancet Neurology Network
    Vol/bind11
    Udgave nummer4
    Sider (fra-til)315-22
    Antal sider8
    ISSN1470-8582
    DOI
    StatusUdgivet - apr. 2012

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF'. Sammen danner de et unikt fingeraftryk.

    Citationsformater